The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's drug for patients with a rare and ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

US FDA approves Nuvation Bio’s taletrectinib for treatment of advanced ROS1-positive non-small cell lung cancer: New York Saturday, June 14, 2025, 14:00 Hrs [IST] Nuvation Bio I ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...

The US Food and Drug Administration (FDA) yesterday approved Nuvation Bio’s (NYSE: NUVB) Ibtrozi (taletrectinib), a kinase ...

He has a track record of turning drug approvals into billion-dollar deals. Patience pays off for this biotech deal © 2025 ...

Recent developments in healthcare reveal a flurry of activity, from potential dietary guideline shifts and FDA approvals of ...

The U.S. Food and Drug Administration said on Wednesday it has approved Nuvation Bio's therapy for patients with a type of ...